{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-025673","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2025-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.574544+00:00","generated_at":"2026-05-18T06:53:12.803149+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Rocket Pharmaceuticals appoints Christopher Stevens as COO; Patel shifts to President, Head of R&D","bullets":["Christopher Stevens, age 45, appointed COO effective July 7, 2025; previously EVP at Spark Therapeutics.","Kinnari Patel transitions from COO, President, Head of R&D to President, Head of R&D.","Stevens receives $525,000 base salary, 45% target bonus, $250,000 sign-on, and ~$2.5M equity grant.","Equity vests over 3 years; additional $500K equity grant after one year.","Severance provisions: 9 months base plus COBRA; 12 months on change-in-control termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-025673","json":"https://secwatch.observer/filing/0001140361-25-025673.json","markdown":"https://secwatch.observer/filing/0001140361-25-025673.md","text":"https://secwatch.observer/filing/0001140361-25-025673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125025673/0001140361-25-025673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036125025673/ef20051920_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:53:12.803149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}